If it weren’t for clinical trials, Gippsland’s Steve Wadey says he wouldn’t be alive today.
Clinical Trials
Adjuvant Vaccine Combo May Prolong Survival in Melanoma
A multipeptide vaccine combination approach may extend survival in stage IIB to IV melanoma.
Pembrolizumab/Vibostolimab Coformulation for Melanoma to be Discontinued
The phase 3 KeyVibe-010 study will discontinue the coformulation of pembrolizumab and vibostolimab treatment for high-risk melanoma due to futility.
Merck Discontinues KeyVibe-010 Trial of Vibostolimab/Pembrolizumab in Resected High-Risk Melanoma
The phase 3 KeyVibe-010 trial (NCT05665595) evaluating the combination of adjuvant vibostolimab (MK-7684A) and pembrolizumab (Keytruda) vs pembrolizumab alone in patients with resected high-risk stage IIB, IIC, III, and IV melanoma has been discontinued.